elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q34008593-3718401F-0FE4-47D5-A551-687A8F8BAB11
Q34008593-3718401F-0FE4-47D5-A551-687A8F8BAB11
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34008593-3718401F-0FE4-47D5-A551-687A8F8BAB11
Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia.
P2860
Q34008593-3718401F-0FE4-47D5-A551-687A8F8BAB11
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34008593-3718401F-0FE4-47D5-A551-687A8F8BAB11
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
85ee96dcb934976826c3d0a77d58d5446089ddd8
P2860
Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG).